ClinicalTrials.gg
RecruitingNCT07403760WISER-AFUpdated Jul 6, 2026

Wellbeing and Survival Improvement With Event Reduction by Ablation for Atrial Fibrillation in the Very Elderly

An interventional study of Catheter Ablation and Sham Control in Atrial Fibrillation (AF), sponsored by Beijing Anzhen Hospital. Recruiting at 1 site in China. Open to participants aged 80 Years and older. Per ClinicalTrials.gov, last updated 2026-07-06.

Sponsored by Beijing Anzhen Hospital · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
136
Allocation
Randomized
Ages
80 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 36 studies in Atrial Fibrillation by Beijing Anzhen Hospital — 25 open to participants now, 26 under way, 1 of them phase 3. Atrial Fibrillation · Beijing Anzhen Hospital.

Planned enrollment
23rd of 24
136 · median 410
Started
2026
with 10 others
No phase
21 of 36
15 open now
Primary completion
2028-11
later than 13 of 25 live
Registered
28th of 36
by date

Among the 36 studies in Atrial Fibrillation by Beijing Anzhen Hospital, this one is the 23rd largest by planned enrollment of the 24 interventional ones that give a count, is one of 11 that started in 2026, is one of 21 with no phase, reaches primary completion later than 13 of the 25 other live ones, and was the 28th registered.

Atrial Fibrillation

4,018 studies on the registry are indexed under Atrial Fibrillation; 965 are open to participants now.

Browse Atrial Fibrillation studies →

Open to participants now

25 of the 36 studies in Atrial Fibrillation by Beijing Anzhen Hospital are open now, in 1 country. Recruiting first, the newest first:

19 more — sign in →

By country, each count listing its studies:

All 25 open studies →

Where they have run

Who these studies take

Of the 613 Atrial Fibrillation studies recruiting now, 410 (67%) set no upper age limit and 44 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.

This study: 80 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 36 studies in Atrial Fibrillation by Beijing Anzhen Hospital, or all of them as a file.
02

Study summary

The WISER-AF trial is a multicenter, double-blind, sham-controlled, randomized controlled trial. It aims to evaluate the efficacy and safety of catheter ablation compared to a sham procedure in improving the quality of life (SF-36 score) in very elderly patients (aged ≥80 years) with symptomatic atrial fibrillation over a 6-month follow-up period.

Read the detailed description

Atrial fibrillation (AF) prevalence increases with age, posing significant challenges in the very elderly (≥80 years). While catheter ablation is an established treatment for general AF patients, its efficacy in improving quality of life (QoL) in the very elderly remains underrepresented in previous trials. The WISER-AF trial is designed to fill this evidence gap. The study will enroll 136 symptomatic AF patients aged ≥80 years in China. Patients will be randomized 1:1 to undergo either catheter ablation or a sham procedure. To ensure blinding, all patients will wear eye masks and headphones during the procedure. The sham group will receive phrenic nerve stimulation to mimic the sensation of ablation without delivering therapeutic energy. The primary endpoint is the change in the SF-36 total score from baseline to 6 months. Secondary endpoints include changes in AFEQT score, Clinical Frailty Scale (CFS), LVEF, NT-proBNP, and cardiovascular events.

03

Conditions studied

  • Atrial Fibrillation (AF)

Browse trials for

Keywords

  • catheter ablation
  • very elderly
  • quality of life
04

Who can participate

Ages eligible
80 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥ 80 years.
  2. Documented paroxysmal or persistent atrial fibrillation by or Holter within 6 months prior to enrollment.
  3. Symptomatic AF (including palpitations, chest tightness, fatigue, dizziness, blackouts, dyspnea).
  4. Voluntary participation and signed .

Exclusion criteria

Exclusion Criteria:

  1. Class IV heart failure.
  2. Acute myocardial infarction, cardiac surgery, or PCI within the past 1 year.
  3. Long-standing persistent AF (duration > 1 year).
  4. Left atrial anteroposterior diameter > 6 cm.
  5. History of prior AF ablation.
  6. AF secondary to reversible causes (e.g., post-surgery, infection, hyperthyroidism).
  7. Severe mitral stenosis.
  8. Moderate to severe hepatic failure ( B-C).
  9. Renal failure stage 4-5 ( \<30 ml/min/1.73m2) or continuous dialysis.
  10. Inability to cooperate due to dementia or severe mental disorder.
  11. Presence of left atrial thrombus.
  12. Prior Left Atrial Appendage Occlusion (LAAO).
  13. to anticoagulation.
  14. \< 1 year.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Outcomes assessor)
Enrollment
136 participants (estimated)

Study arms

  • Experimental
    Catheter Ablation Group

    Procedure: Catheter Ablation

  • Sham comparator
    Sham Control Group

    Procedure: Sham Control

Interventions

  • ProcedureCatheter Ablation

    Patients undergo PVI (for paroxysmal AF) or PVI +linear ablation+EI-VOM(for persistent AF). All patients will wear eye masks and headphones with music during the procedure.

  • ProcedureSham Control

    Patients undergo femoral vein puncture and catheter placement. Phrenic nerve stimulation is performed to mimic procedural sensations. No ablation energy is delivered. All patients will wear eye masks and headphones with music during the procedure. Patients remain in the lab for at least 60 minutes (for paroxysmal AF) or 90 minutes (for persistent AF).

06

What researchers measure

Primary outcomes

  1. Change in SF-36 Total Score

    Difference in the change of the Medical Outcomes Study 36-Item Short Form Health Survey (SF-36) total score from baseline to 6 months between the two groups.

    Time frame: Baseline, 6 months

Secondary outcomes

  1. Change in AFEQT Score

    Change in Atrial Fibrillation Effect on Quality-of-Life (AFEQT) score

    Time frame: Baseline, 6 months

  2. Change in Clinical Frailty Scale (CFS) Score

    Change in frailty status assessed by CFS

    Time frame: Baseline, 6 months

  3. Change in Left Ventricular Ejection Fraction (LVEF)

    Time frame: Baseline, 6 months

  4. Change in NT-proBNP level

    Time frame: Baseline, 6 months

  5. Freedom from Atrial Arrhythmias

    Absence of atrial fibrillation, atrial flutter, or atrial tachycardia recorded by ECG, Holter, or patch monitor after a 30-day blanking period.

    Time frame: 6 months

  6. Incidence of Composite Cardiovascular Outcome

    Composite of all-cause death, stroke or systemic embolism, myocardial infarction, major bleeding, and heart failure hospitalization/emergency visits.

    Time frame: 6 months

  7. Healthcare Resource Utilization

    Number of emergency room visits and unplanned hospitalizations

    Time frame: 6 months

Other outcomes

  1. Safety Outcome

    Composite of all-cause death, stroke, serious adverse events and complications

    Time frame: 6 months

07

Study locations

1 of 1 sites recruiting
  • Beijing Anzhen Hospital, Capital Medical University, Beijing, China
    Beijing, China
    Recruiting
    • Liu He, PhD. · Contacttheliu@139.com · +86 13810720787
    • Changsheng Ma, Prof. · Principal investigator
    • Ning Zhou, Prof. · Principal investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jul 2026; primary completion for Nov 2028, 28 months later.

Of 797 non-industry interventional studies with no phase under Atrial Fibrillation, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 59. This study's planned 28 months is below that.

Counting every sponsor, half of 1,052 studies reached it within 33 months; a quarter within 18 and three quarters within 54.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 4, 2026
First posted
Feb 11, 2026
StartEst.
Jul 1, 2026
Primary completionEst.
Nov 30, 2028
CompletionEst.
Dec 30, 2028
Last update
Jul 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07403760
Responsible party
Sponsor
First posted
Feb 11, 2026
Start date
Jul 1, 2026 (estimated)
Primary completion
Nov 30, 2028 (estimated)
Completion
Dec 30, 2028 (estimated)
Last update
Jul 6, 2026

Study contacts

Liu He, PhD
Contact
theliu@139.com
+86 13810720787
Changsheng Ma, Prof.
principal investigator · Beijing Anzhen Hospital
Ning Zhou, Prof.
principal investigator · Beijing Anzhen Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion